AOA Dx was founded by 3 entrepreneurs after working together for over 10 years within the women’s health industry
Led by Joyance Partners, the round included notable investments from Avestria Ventures, AlleyCorp, Launchpad Venture Group, TBD Angels and Kyto Technology and Life Science, among others
Analyzed 500 retrospective samples reflective of intended use population in ovarian cancer
AOA Dx’s scientific collaboration partner, Professor Uri Saragovi of McGill University, was awarded a $650,000 CAD grant for further development of AKRIVIS GD™
Led by Avestria Ventures with funds from Y Combinator, AlleyCorp, The Helm, RH Capital, Olive Tree Capital and other notable investors, the round gives AOA Dx the ability to develop the the AKRIVIS GD™ assay and expand their full-time team
Liquid chromatography-mass spectrometry (LC-MS) technology results support the development of liquid biopsy platform for multiple cancer indications for the detection of Tumor Marker Gangliosides in serum
First patient enrolled in the OVERT prospective study
“GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer” is published, highlighting the power of biomarkers GD2 and GD2 as an ovarian cancer diagnostic
A top Key Opinion Leader in ovarian cancer, Dr. Elias, Director of Gynecologic Oncology Laboratory at Brigham and Women's Hospital and Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, is selected as a leading physician and study coordinator
Led by Good Growth Capital with participation from strategic diagnostic investor Labcorp Venture Fund and other leading investors including RH Capital, Y Combinator, Astia Fund and Adaptive Capital Partners, the funding allows AOA Dx to open new lab facilities, expand the OVERT study, and further develop the GlycoLocate™ platform
“The cancer glycocade as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides” is published, highlighting the power of tumor-marker gangliosides to detect cancer, even at the earliest stages
AOA Dx opens their first headquarter lab, providing the team with space and equipment to complete in-house research and development
AOA Dx was named the Colorado BioScience Association’s Rising Star of the Year, recognizing the company’s scientific innovation and leadership in advancing early ovarian cancer detection.
AOA Dx presented new data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating the potential of its AI-powered multi-omic platform for early ovarian cancer detection, based on collaborative research with the University of Colorado Anschutz Medical Campus and The University of Manchester.
AOA Dx published peer-reviewed research in Cancer Research Communications demonstrating the potential of a multi-omic blood-based approach for early ovarian cancer detection, based on collaborative studies with the University of Colorado Anschutz Medical Campus and The University of Manchester.
AOA Dx published peer-reviewed clinical evidence in Diagnostics evaluating its multi-omic machine-learning model for the detection of early-stage ovarian cancer in symptomatic women, advancing real-world clinical assessment of multi-omic diagnostics.
